IN THE CLAIMS:

Please amend the claims as follows:

1. (Previously Presented) A pharmaceutically acceptable solid anthelmintic formulation comprising a combination of a first active ingredient comprising particles of an avermectin that had been spray granulated with polyethylene glycol around the particles; a second active ingredient comprising an anthelmintic pyrimidine; a third active ingredient comprising a hexahydropyrazinoisoquinoline; and a fourth active ingredient comprising a benzimidazole or probenzimidazole.

2. (Previously Presented) The formulation of claim 1, wherein the first active ingredient comprises ivermectin.

3. (Previously Presented) The formulation of claim 1, comprising at least about 0.005% ivermectin.

4. (Previously Presented) The formulation of claim 1, comprising about 0.012 - 5% ivermectin.

5. (Previously Presented) The formulation of claim 1, comprising a tetrahydropyrimidine.

6. (Previously Presented) The formulation of claim 1, wherein the second active ingredient comprises a pyrantel.

7. (Previously Presented) The formulation of claim 6, wherein the pyrantel comprises pyrantel pamoate.

8. (Previously Presented) The formulation of claim 1, comprising at least about 1.5% pyrantel.

9. (Previously Presented) The formulation of claim 1, comprising about 11.2 - 33% pyrantel.

10. (Previously Presented) The formulation of claim 1, wherein the third active ingredient comprises praziquantel.

11. (Previously Presented) The formulation of claim 1, comprising at least about 2.0% praziquantel.

12. (Previously Presented) The formulation of claim 1, comprising about 8.2 - 23% praziquantel.

13. (Previously Presented) The formulation of claim 1, comprising at least about 25.3% fenbendazole.

14. (Previously Presented) The formulation of claim 1, comprising about 30.0 - 45.0% fenbendazole.

15. (Previously Presented) The formulation of claim 1, comprising at least about 15.2% febantel.

16. (Previously Presented) The formulation of claim 1, comprising about 19.4 - 31.6% febantel.

17. (Previously Presented) The formulation of claim 2, in a form that will remain stable and pharmaceutically active, in a solid form, for over one month.

18. (Previously Presented) The formulation of claim 17, wherein there is an effective amount of polyethylene glycol to prevent the ivermectin from degrading sufficiently to eliminate its pharmaceutical effectiveness.

19. (Cancelled)

20. (Cancelled)

21. (Previously Presented) A method for forming an anthelmintic formulation comprising the steps of:

(A) preparing a combination of ivermectin and polyethylene glycol;

(B) spray granulating the combination to form granules, with the polyethylene glycol covering the ivermectin; and

(C) combining the granules with an additional active ingredient composition.

22. (Previously Presented) The method of claim 21, wherein the additional active ingredient composition comprises pyrantel pamoate, praziquantel, and fenbendazole or febantel.

23. (Previously Presented) The method of claim 21, wherein the formulation is pressed into a tablet or enclosed in a capsule and the ivermectin has been effectively isolated, so that the formulation will stay stable for over one month.

24. (Previously Presented) An anthelmintic formulation, which is formed by the method of claim 21.

25. (Previously Presented) A method of controlling helminth infestation in animals, comprising the step of administering a pharmaceutically effective amount of the formulation of claim 2 to an animal in need thereof.

26. (Previously Presented) The method of claim 25, wherein the animal is a dog or cat.

27. (Previously Presented) The method of claim 25, wherein the administration comprises administering 5 - 7 μg/Kg body weight of the dog or cat.

28-34. (Canceled)